Drug-induced diseases: approaches to diagnosis, correction  and prevention. Pharmacovigilance

Sychev, D.A.; Остроумова, О. Д.; Переверзев, А. П.; Кочетков, А. И.; Остроумова, Т. М.; Klepikova, M.V. Klepikova; Alyautdinova, I.A. Alyautdinova; Васильевна, Голобородова Ирина

doi:10.18565/pharmateca.2020.6.113-126

Cited by 23 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drug-induced MetS is a combination of such conditions as abdominal obesity, hypercholesterolemia, hyperglycemia, and high blood pressure which occur while taking drugs [12]. Drug-induced MetS can be associated with various drugs, including psychotropic drugs [13]. Among psychotropic drugs, antipsychotics and valproic acid (VPA) drugs are the most common cause of drug-induced MetS [1,14] (Figure 2).…”

Section: Introductionmentioning

confidence: 99%

Valproate-Induced Metabolic Syndrome

Shnayder,

Grechkina,

Trefilova

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Valproic acid (VPA) and its salts (sodium calcium magnesium and orotic) are psychotropic drugs that are widely used in neurology and psychiatry. The long-term use of VPA increases the risk of developing adverse drug reactions (ADRs), among which metabolic syndrome (MetS) plays a special role. MetS belongs to a cluster of metabolic conditions such as abdominal obesity, high blood pressure, high blood glucose, high serum triglycerides, and low serum high-density lipoprotein. Valproate-induced MetS (VPA-MetS) is a common ADR that needs an updated multidisciplinary approach to its prevention and diagnosis. In this review, we consider the results of studies of blood (serum and plasma) and the urinary biomarkers of VPA-MetS. These metabolic biomarkers may provide the key to the development of a new multidisciplinary personalized strategy for the prevention and diagnosis of VPA-MetS in patients with neurological diseases, psychiatric disorders, and addiction diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Valproate-Induced Metabolic Syndrome

Shnayder,

Grechkina,

Trefilova

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Определение причинно-следственной связи между приемом ЛС и развитием ЛИП, как и любой НР ЛС, диктует необходимость очень тщательного сбора фармакологического анамнеза, для этой цели предложен специальный алгоритм [6,11].…”

Section: Introductionunclassified

Antineoplastic agents associated with the development of drug-induced pancreatitis

2021

View full text Add to dashboard Cite

The frequency of drug-induced pancreatitis (LIP) is from 2 to 5% of all cases of acute pancreatitis (OP), but it is much more common in risk groups – among children and HIV-infected patients. The use of a number of drugs (drugs) is associated with the development of lipids, among them a special place is occupied by antitumor drugs due to the great medical and social significance of oncological diseases and the appearance in recent years of a large number of new antitumor drugs. The purpose of this review was to review the literature data on antitumor drugs, the use of which is associated with the development of lipids. LI OP developed in 1.8% of patients treated with nivolumab or pembroluzumab. In total, in 14 phase 1-3 studies on the efficacy and safety of ipilimumab, the development of OP was reported in less than 1% of the subjects. Therapy with molecular-targeted targeted drugs, such as tyrosine kinase inhibitors (TKI) or other representatives of the kinase inhibitor class, is also associated with the development of OP. The HP database of the World Health Organization (WHO, World Health Organization Adverse Drug Reaction database) contains reports of individual clinical cases of OP development during treatment with proteosome inhibitors and antibody-drug conjugates. It is known that the following antitumor drugs are also associated with the development of pancreatitis: 6-mercaptopurine, L-asparaginase, tamoxifen, cisplatin, cytarabine, ifosfamide, paclitaxel, docetaxel, oxaliplatin, capecitabine, periwinkle alkaloids, cytosine, cisplatin, interferon alpha-2b, doxorubicin, tamoxifen, gefitinib, vinorelbine, levamizole, methotrexate, 5-fluorouracil, capecitabine, trans-retinoic acid.

show abstract

Drug-Induced Cognitive Impairment and Dementia

Ostroumova,

Kochetkov

et al. 2024

Neurosci Behav Physi

View full text Add to dashboard Cite

Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance

Cited by 23 publications

References 0 publications

Valproate-Induced Metabolic Syndrome

Valproate-Induced Metabolic Syndrome

Antineoplastic agents associated with the development of drug-induced pancreatitis

Drug-Induced Cognitive Impairment and Dementia

Contact Info

Product

Resources

About